Muscular dystrophy affects approximately 1 in 3,300 people globally. More than 90% of people with Duchenne muscular dystrophy die from respiratory complications. The market for related treatments is expanding, with registered clinical trials increasing 18% over a recent three-year period.
Key Takeaways
- 1 in 3,300 people are estimated to have muscular dystrophy worldwide.
- About 30%–40% of DMD patients develop dilated cardiomyopathy (DCM).
- Approximately 50% of DMD patients develop scoliosis.
- In DMD, nonsense mutations account for roughly 10%–15% of cases.
- In DMD, approximately 10%–15% of patients have duplications of one or more exons.
- Cardiac care guidelines for DMD recommend starting ACE inhibitors and/or beta-blockers by early signs of cardiomyopathy, typically by age 10–12 years.
- The global neuromuscular disorders therapeutics market was $5.5 billion in 2023.
- The US rare disease therapeutics market was $136.0 billion in 2023 (includes rare disease indications such as muscular dystrophy).
- Global gene therapy market revenue reached $2.2 billion in 2022.
- FDA accelerated approval: Vyondys 53 (golodirsen) received accelerated approval on 12 December 2019.
- FDA approval: Amondys 45 (casimersen) received approval on 19 February 2021.
- In 2023, FDA had 87 total drug approvals; 52 were novel molecular entities (NME).
- DMD patients who receive corticosteroids had a median survival into the 30s in modern cohorts (reported in clinical guidance summarizing observational data).
- In a meta-analysis, exons-skipping therapy with eteplirsen increased dystrophin levels to a mean of 0.9% compared with baseline levels.
- The phase 3 DELOS trial for reldesemtive measured effects on the 6-minute walk distance (6MWD); mean difference favored reldesemtive vs placebo (reported as statistically significant).
About 1 in 3,300 people worldwide have muscular dystrophy, with Duchenne driving major heart, breathing, and access impacts.
Related reading
01 · Category
Disease Burden9 stats
01
1 in 3,300 people are estimated to have muscular dystrophy worldwide.
02
About 30%–40% of DMD patients develop dilated cardiomyopathy (DCM).
03
Approximately 50% of DMD patients develop scoliosis.
04
A 2015 study estimated the global prevalence of DMD at 2.5 per 100,000 people.
05
Up to 90% of DMD patients die from respiratory complications.
06
Limb-girdle muscular dystrophies (LGMDs) have an estimated prevalence of 1–9 per 100,000 in European populations.
07
DMD is the most common muscular dystrophy in children.
08
In the UK, the prevalence of DMD has been estimated at about 1.5 per 10,000 people.
09
In a systematic review, the median age at loss of ambulation for DMD was 12 years.
Interpretation
Disease Burden Interpretation
From a disease burden perspective, muscular dystrophy affects about 1 in 3,300 people worldwide, while the severe downstream impact in Duchenne muscular dystrophy is stark with up to 90% of patients dying from respiratory complications and around half developing scoliosis.
02 · Category
Industry Trends10 stats
01
In DMD, nonsense mutations account for roughly 10%–15% of cases.
02
In DMD, approximately 10%–15% of patients have duplications of one or more exons.
03
Cardiac care guidelines for DMD recommend starting ACE inhibitors and/or beta-blockers by early signs of cardiomyopathy, typically by age 10–12 years.
04
Patient advocacy groups reported that 10+ new DMD natural history studies were initiated or updated between 2019 and 2022 (counted in review).
05
In DMD testing, next-generation sequencing (NGS) has become the primary method for identifying mutation types, with reported diagnostic yields above 90% in cohorts.
06
Exon-skipping therapeutics target specific deletions/skipable exons, and the number of amenable exons/variants drives companion diagnostics demand; reported target exon coverage is 10–12 exons for common DMD mutations.
07
The number of registered clinical trials for muscular dystrophy increased by 18% from 2019 to 2022 (based on ClinicalTrials.gov query counts in a published analysis).
08
A bibliometric analysis found that China accounted for 33% of muscular dystrophy publications in 2010–2020 (global share).
09
In a global HTA comparison, 1 of 5 major European payers required additional evidence for DMD therapies due to uncertainty in long-term benefits.
10
DMD newborn screening feasibility work reported that targeted genetic testing could identify affected infants within 2–4 weeks of sample collection (modeled timelines).
Interpretation
Industry Trends Interpretation
Industry Trend: As DMD research and testing evolve, the field is increasingly structured around actionable mutation and care timelines, including that nonsense mutations and exon duplications each affect about 10% to 15% of patients and that cardiac preventative treatment is typically initiated by around age 1.
03 · Category
Market Size11 stats
01
The global neuromuscular disorders therapeutics market was $5.5 billion in 2023.
02
The US rare disease therapeutics market was $136.0 billion in 2023 (includes rare disease indications such as muscular dystrophy).
03
Global gene therapy market revenue reached $2.2 billion in 2022.
04
The global exons-skipping therapy market was estimated at $1.4 billion in 2022.
05
In 2023, the global antisense oligonucleotide (ASO) therapies market was valued at $1.6 billion.
06
The Duchenne muscular dystrophy therapeutics market in the US was projected to reach $6.2 billion by 2030 (from 2023 baseline).
07
The global muscular dystrophy therapeutics market was projected to reach $9.5 billion by 2030 (from 2023).
08
The global corticosteroids market was $17.3 billion in 2023 (used in DMD care regimens).
09
The global ventilator market was $29.8 billion in 2023 (respiratory care relevant to progressive muscular dystrophies).
10
The global orthotics and prosthetics market was $6.6 billion in 2023 (relevant to muscle weakness, scoliosis, and mobility aids).
11
The global rare disease diagnostics market was $10.5 billion in 2023 (including testing for muscular dystrophy genes).
Interpretation
Market Size Interpretation
For the Market Size view, the sector is expanding from $5.5 billion globally in 2023 for neuromuscular disorder therapeutics and is supported by adjacent market strength such as the $6.2 billion US Duchenne therapeutics projection by 2030, alongside sizable gene therapy at $2.2 billion in 2022 and exons skipping therapy at $1.4 billion in 2022.
More related reading
04 · Category
Regulatory & Approvals5 stats
01
FDA accelerated approval: Vyondys 53 (golodirsen) received accelerated approval on 12 December 2019.
02
FDA approval: Amondys 45 (casimersen) received approval on 19 February 2021.
03
In 2023, FDA had 87 total drug approvals; 52 were novel molecular entities (NME).
04
EMA conditional marketing authorization allows medicines to be approved for serious unmet needs based on less comprehensive data, subject to specific obligations.
05
FDA Breakthrough Therapy designation for DMD-targeted therapies is granted when preliminary clinical evidence indicates substantial improvement over available therapy.
Interpretation
Regulatory & Approvals Interpretation
From 12 December 2019 to 19 February 2021 the FDA granted accelerated approval for Vyondys 53 and approval for Amondys 45 in DMD, and in 2023 it approved 87 drugs including 52 novel molecular entities, underscoring how regulatory pathways are actively enabling new therapies while EMA conditional marketing and FDA Breakthrough Therapy designations support medicines for serious unmet needs.
05 · Category
Clinical Outcomes6 stats
01
DMD patients who receive corticosteroids had a median survival into the 30s in modern cohorts (reported in clinical guidance summarizing observational data).
02
In a meta-analysis, exons-skipping therapy with eteplirsen increased dystrophin levels to a mean of 0.9% compared with baseline levels.
03
The phase 3 DELOS trial for reldesemtive measured effects on the 6-minute walk distance (6MWD); mean difference favored reldesemtive vs placebo (reported as statistically significant).
04
The 2-year outcome in a landmark observational cohort showed that DMD respiratory function declines with mean FVC percentage predicted decreasing over time (reported in cohort paper).
05
A systematic review reported that nocturnal noninvasive ventilation in neuromuscular diseases improves survival with an increase in median survival time of approximately 1–2 years (varies by study).
06
In DMD, early initiation of cardiac medications (ACE inhibitors/β-blockers) is associated with delayed onset of cardiomyopathy progression by several years in observational studies (reported ranges in guidance review).
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes for muscular dystrophy, the strongest trend is that modern DMD care can shift real-world survival and function, with corticosteroid-treated patients showing median survival into the 30s while targeted therapies like eteplirsen raise dystrophin levels to about 0.9% on average, reflecting measurable benefits beyond laboratory markers.
06 · Category
Cost & Access5 stats
01
In a 2018 paper, the total annual cost per patient for common DMD therapies (including corticosteroids and mutation-specific exon-skipping) was estimated at $400,000+ in some scenarios.
02
In a review of patient access, 1 in 3 families reported delays in obtaining DMD treatments due to insurance and authorization processes.
03
In a 2021 US survey of caregivers of children with rare diseases, 45% reported that the cost of care was a major financial burden (applies to rare disease families including muscular dystrophy).
04
In DMD, out-of-pocket costs for families can exceed $5,000per year for some households, as reported in US survey-based studies.
05
A 2020 study reported that rare disease patients faced median travel distance of 25 miles for specialty care in the US.
Interpretation
Cost & Access Interpretation
Cost and access challenges for muscular dystrophy are already hitting families hard, with one in three reporting insurance and authorization delays and 45% of rare disease caregivers saying the cost of care is a major burden, while out of pocket expenses can top $5,000 per year and travel for specialty treatment averages 25 miles.
report visual · Breakdown
Common DMD complication rates and impact
Key complications reported in DMD include dilated cardiomyopathy, scoliosis, and respiratory-related mortality.
90%
Up to 90% of DMD patients die from respiratory complications.
10%
In DMD, nonsense mutations account for roughly 10%–15% of cases.
source-verifiedncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Alexander Schmidt. (2026, February 13). Muscular Dystrophy Statistics. Gitnux. https://gitnux.org/muscular-dystrophy-statistics
MLA
Alexander Schmidt. "Muscular Dystrophy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/muscular-dystrophy-statistics.
Chicago
Alexander Schmidt. 2026. "Muscular Dystrophy Statistics." Gitnux. https://gitnux.org/muscular-dystrophy-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+32 additional datasets cited (not shown individually)